Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature

• Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable. • Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation. • Next-generation sequencing may play an important com...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Andrea M., Argenta, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481173/
https://www.ncbi.nlm.nih.gov/pubmed/37680504
http://dx.doi.org/10.1016/j.gore.2023.101264
_version_ 1785101917367566336
author Johnson, Andrea M.
Argenta, Peter A.
author_facet Johnson, Andrea M.
Argenta, Peter A.
author_sort Johnson, Andrea M.
collection PubMed
description • Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable. • Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation. • Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.
format Online
Article
Text
id pubmed-10481173
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104811732023-09-07 Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature Johnson, Andrea M. Argenta, Peter A. Gynecol Oncol Rep Case Report • Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable. • Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation. • Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies. Elsevier 2023-08-23 /pmc/articles/PMC10481173/ /pubmed/37680504 http://dx.doi.org/10.1016/j.gore.2023.101264 Text en © 2023 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Johnson, Andrea M.
Argenta, Peter A.
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title_full Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title_fullStr Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title_full_unstemmed Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title_short Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature
title_sort angiosarcoma of the ovary treated with polyadenosine ribose polymerase inhibition, a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481173/
https://www.ncbi.nlm.nih.gov/pubmed/37680504
http://dx.doi.org/10.1016/j.gore.2023.101264
work_keys_str_mv AT johnsonandream angiosarcomaoftheovarytreatedwithpolyadenosineribosepolymeraseinhibitionacasereportandreviewoftheliterature
AT argentapetera angiosarcomaoftheovarytreatedwithpolyadenosineribosepolymeraseinhibitionacasereportandreviewoftheliterature

Ejemplares similares